EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Human monoclonal IgG antibodies derived from a patient allergic to birch pollen as tools to study the in situ localization of the major birch pollen allergen, Bet v 1, by immunogold electron microscopy






Journal of Allergy and Clinical Immunology 101(1 Pt 1): 60-66

Human monoclonal IgG antibodies derived from a patient allergic to birch pollen as tools to study the in situ localization of the major birch pollen allergen, Bet v 1, by immunogold electron microscopy

Human monoclonal antibodies (BAB1, BAB2 and BAB4), derived from an individual allergic to pollen of white birch (Betula verrucosa) [B. pendula], were incubated with ultrathin sections of birch pollen grains and binding sites were determined by scanning electron microscopy. Purified human monoclonal antibodies bound specifically to nitrocellulose-blotted natural and recombinant Bet v 1. A p-loop-like motif consisting of GXGGXG followed by a lysine, serine and/or threonine was identified starting at amino acid 47, and the high-degree of conservation of the p-loop-containing motif was also shown by comparing the Bet v 1-derived polypeptide with the databases. The loop-core motif (GNGGPG) was conserved in all sequences of Bet v 1 isovariants and in all Bet v 1-homologous allergens submitted to GenBank. It is concluded that a possible function of the Bet v 1 protein as a nucleotide-binding protein would be in accordance with the immunolocalization of the allergen to ribosome-rich cell areas and the nucleus, and it may explain why many atopic individuals are cross-sensitized against these conserved proteins.


Accession: 003162994

PMID: 9449502

DOI: 10.1016/S0091-6749(98)70194-0



Related references

Grote, M.; Wiedemann, P.; Lebecque, S.; Valenta, R., 1998: Human monoclonal IgG antibodies derived from a patient allergic to birch pollen as tools to study the in situ localization of major birch pollen allergen, Bet v 1, by immunogold electron microscopy. Background: Bet v 1, the major birch pollen allergen, and related allergens present in various tree pollens, fruits, and vegetables represent a family of important cross-reactive allergens. Although the DNA, deduced amino-acid sequence, and struct...

Grote, M.; Hayek, B.; Reichelt, R.; Kraft, D.; Valenta, R., 2000: Immunogold electron microscopic localization of the cross-reactive two-EF-hand calcium-binding birch pollen allergen Bet v 4 in dry and rehydrated birch pollen. Recently, a novel family of low-molecular-weight (8-9 kD), two-EF-hand calcium-binding proteins has been described as allergens in plant pollens. Approximately 10% of pollen-allergic patients have IgE antibodies which cross-react with the two-EF-h...

Grote, M., 1991: Immunogold electron microscopy of soluble proteins: localization of Bet v I major allergen in ultra-thin sections of birch pollen after anhydrous fixation techniques. To localize the highly water-soluble major allergen Bet v I in ultra-thin sections of birch pollen, pollen grains were cracked, air-dried, and processed for electron microscopy using one of the following preparation techniques: fixation in aqueous...

Larenas-Linnemann, Désirée., 2010: Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen. Oralair Birch is a dissolving tablet being developed for sublingual immunotherapy (SLIT) of allergic rhinitis caused by birch pollen allergy. Oralair Birch is being developed by Stallergenes SA and Canadian licensee Paladin Labs Inc. Oralair Birch...

Smole, U.; Radauer, C.; Lengger, N.; Svoboda, M.; Rigby, N.; Bublin, M.; Gaier, S.; Hoffmann-Sommergruber, K.; Jensen-Jarolim, E.; Mechtcheriakova, D.; Breiteneder, H., 2016: The major birch pollen allergen Bet v 1 induces different responses in dendritic cells of birch pollen allergic and healthy individuals. Dendritic cells play a fundamental role in shaping the immune response to allergens. The events that lead to allergic sensitization or tolerance induction during the interaction of the major birch pollen allergen Bet v 1 and dendritic cells are no...

Gafvelin, G.; Thunberg, S.; Kronqvist, M.; Grönlund, H.; Grönneberg, R.; Troye-Blomberg, M.; Akdis, Mübeccel.; Fiebig, H.; Purohit, A.; Horak, F.; Reisinger, Jürgen.; Niederberger, V.; Akdis, C.A.; Cromwell, O.; Pauli, G.; Valenta, R.; van Hage, M., 2005: Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Background: Recently, recombinant hypoallergenic derivatives of the major birch pollen allergen, Bet v 1, were used to treat birch-pollen-allergic patients in a double-blind, placebo-controlled, multi-centre immunotherapy study. The aim of this st...

Nopp, A.; Halldén, G.; Lundahl, J.; Johansson, E.; Vrtala, S.; Valenta, R.; Grönneberg, R.; Van Hage-Hamsten, M., 2000: Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. Background: Nearly 60% of birch pollen-allergic patients react exclusively to Bet v 1. With use of the skin blister model, previously only established for installation of crude allergens, we have for the first time characterized the inflammatory r...

Van Hage Hamsten, M.; Johansson, E.; Roquet, A.; Peterson, C.; Andersson, M.; Vrtala, S.; Valenta, R.; Gronneberg, R., 2001: Recombinant derivatives of the major birch pollen allergen Bet v 1, which induce fewer symptoms and lower mediator release and eosinophil activation than rBet v 1 wild-type in nasal challenges in birch pollen allergic patients. Allergy (Copenhagen) 56(Supplement 68): 94

Denepoux, S.; Eibensteiner, P.B.; Steinberger, P.; Vrtala, S.; Visco, V.; Weyer, A.; Kraft, D.; Banchereau, J.; Valenta, R.; Lebecque, S., 2000: Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. We report the molecular characterization of five human monoclonal antibodies, BAB1-5 (BAB1: IgG(1); BAB4: IgG(2); BAB2, 3, 5: IgG(4)), with specificity for the major birch pollen allergen, Bet v 1. BAB1-5 were obtained after immunotherapy and cont...

Denépoux, S.; Eibensteiner, P.B.; Steinberger, P.; Vrtala, S.; Visco, V.; Weyer, A.; Kraft, D.; Banchereau, J.; Valenta, R.; Lebecque, S., 2000: Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. We report the molecular characterization of five human monoclonal antibodies, BAB1-5 (BAB1: IgG(1); BAB4: IgG(2); BAB2, 3, 5: IgG(4)), with specificity for the major birch pollen allergen, Bet v 1. BAB1-5 were obtained after immunotherapy and cont...